Phaseline

Companies › Pop Test Oncology

Pop Test Oncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Org-34517 (PT150)
Glucocorticoid receptor antagonist
NR3C1Phase 1Alcohol Use DisorderJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06712602Org-34517 (PT150)Phase 1Alcohol Use DisorderPsychiatryJul 2028

Targets

NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Laboratorios Sophia S.A de C.V. Optinose US Santhera Pharmaceuticals Pacira Pharmaceuticals Tiohundra

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.